🔥 Premium AI-powered Stock Picks from InvestingPro Now up to 50% OffCLAIM SALE

Microcap stock jumps 8% after it secured a contract from UNICEF to supply antibiotic product

Published 13-06-2024, 02:34 pm
Microcap stock jumps 8% after it secured a contract  from UNICEF to supply antibiotic product

Share price of a company among the 10 leading fixed-dosage injectable manufacturers in the world, surged 8.4 percent to Rs. 384.95 in Thursday’s trading session, after the company secured a supply contract for its antibiotic product Ceftriaxone from UNICEF.

At 01:01 p.m., the shares of Venus Remedies Ltd (NS:VENR) were trading in the green at Rs. 382.05, up by 7.6 percent, as against its previous closing price of Rs. 355.15, with a market capitalisation of Rs. 510.7 crore.

Is Venus Remedies a buy or sell? Click here to get an InvestingPro subscription for a special discount of 72% at an unbelievable price of only Rs 196 per month

The above link works best from a laptop/desktop and not apps.

Venus Remedies informed the stock exchanges about securing a supply contract for its antibiotic product, Ceftriaxone 1gm, from UNICEF in the Beta Lactam tender.

“UNICEF’s decision to award the tender to Venus Remedies Limited is a testament to our relentless pursuit of excellence in healthcare. Our Ceftriaxone 1gm product has met and surpassed stringent quality criteria, demonstrating our dedication to producing top-tier pharmaceutical solutions,” the company mentioned in the filings.

Earlier on 11th March, the company secured Good Manufacturing Practices (GMP) approval from the UNICEF to supply Cephalosporin antibiotics for treating infections.

On a quarter-on-quarter basis, the company’s consolidated revenue from operations stood at Rs. 195.2 crore in Q4 FY23-24, increasing by 36 percent from Rs. 143.42 crore in Q3 FY23-24.

The after-tax profit grew from Rs. 6.85 crore in Q3 FY23-24 to Rs. 10.51 crore in Q4 FY23-24, indicating a growth of 53.4 percent YoY.

The return on equity (ROE) stood at 5.84 percent in FY23-24, up from 5.77 percent in FY22-23, and a rise in the Return on Capital Employed (ROCE) from 7.37 percent in FY22-23 to 8.17 percent in FY23-24.

The stock has delivered positive returns of nearly 63 percent in one year, but around 3.4 percent of negative returns in the last six months.

Venus Remedies Limited is one of the handful player in the pharmaceutical sector to launch injectables globally, and has manufacturing facilities in Panchkula and Baddi, and an R&D centre under the name of Venus Medicine Research Centre (in India).

Introducing InvestingPro

Through InvestingPro, you can beat the markets with premium insights:

  • Find Undervalued/Overvalued Stocks: Reveal the unbiased Fair Value of any stock based on 1,200+ premium metrics, covering 180,000+ companies worldwide.
  • Instant Financial Bottom Line: Make fully-informed investing decisions with ProTips, bite-size insights that flag risks and rewards on any stock.
  • Discover Overlooked Stocks With Pre-Built Screeners: Find the ideal value stocks to match your investing style, all based on 100% trusted data.
  • Get AI-Enhanced Stock Picks: Receive regularly updated ProPicks for any investing strategy, each with a proven track record to beat the S&P 500
  • Boost Your Picks with Data: Instantly see a company's long-term sustainability and Financial Health to know if it's truly a solid investment.
  • Always Pick the Winner: Make instant Peer Comparisons based on over a dozen valuation benchmarks to ensure you always select a top dog.
  • Get Ideas From Top-Performing Portfolios: See the investments of any firm, fund or private investor with over $100 million in holding assets to discover new ideas.

Now, coming to the great news! For the benefit of our users, we have reduced the prices on all of our Pro and Pro+ plans by almost 72% for a limited period.

Click here to get an InvestingPro subscription for a special discount of 72% at an unbelievable price of only Rs 196 per month

The above link works best from a laptop/desktop and not apps.

Written by Shivani Singh


The views and investment tips expressed by investment experts/broking houses/rating agencies on tradebrains.in are their own, and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Dailyraven Technologies or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor before investing.

The post Microcap stock jumps 8% after it secured a contract from UNICEF to supply antibiotic product appeared first on Trade Brains.

Read More

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.